These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36988996)

  • 21. Cytokine changes in sickle-cell disease patients as markers predictive of the onset of delayed hemolytic transfusion reactions.
    Chadebech P; de Ménorval MA; Bodivit G; Jouard A; Pakdaman S; Lelong F; Habibi A; Galactéros F; Lecron JC; Pirenne F
    Cytokine; 2020 Dec; 136():155259. PubMed ID: 32920319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe neurologic complication after delayed hemolytic transfusion reaction in 2 children with sickle cell anemia: significant diagnosis and therapeutic challenges.
    Elenga N; Mialou V; Kebaïli K; Galambrun C; Bertrand Y; Pondarre C
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):928-30. PubMed ID: 19131783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes.
    Habibi A; Mekontso-Dessap A; Guillaud C; Michel M; Razazi K; Khellaf M; Chami B; Bachir D; Rieux C; Melica G; Godeau B; Galacteros F; Bartolucci P; Pirenne F
    Am J Hematol; 2016 Oct; 91(10):989-94. PubMed ID: 27348613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease.
    Gardner K; Hoppe C; Mijovic A; Thein SL
    Br J Haematol; 2015 Sep; 170(6):745-56. PubMed ID: 25967919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease.
    Mekontso Dessap A; Pirenne F; Razazi K; Moutereau S; Abid S; Brun-Buisson C; Maitre B; Michel M; Galacteros F; Bartolucci P; Habibi A
    Am J Hematol; 2016 Dec; 91(12):1181-1184. PubMed ID: 27538126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe.
    Ferlis M; Lipato T; Roseff SD; Smith WR
    Eur J Haematol; 2022 Nov; 109(5):586-589. PubMed ID: 35848827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Catastrophic Delayed Hemolytic Transfusion Reaction in a Patient With Sickle Cell Disease Without Alloantibodies: Case Report and Review of Literature.
    Jasinski S; Glasser CL
    J Pediatr Hematol Oncol; 2019 Nov; 41(8):624-626. PubMed ID: 30179992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death.
    Chadebech P; Habibi A; Nzouakou R; Bachir D; Meunier-Costes N; Bonin P; Rodet M; Chami B; Galacteros F; Bierling P; Noizat-Pirenne F
    Transfusion; 2009 Sep; 49(9):1785-92. PubMed ID: 19413729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-s antibody-associated delayed hemolytic transfusion reaction in patients with sickle cell anemia.
    Kalyanaraman M; Heidemann SM; Sarnaik AP; Meert KL; Sarnaik SA
    J Pediatr Hematol Oncol; 1999; 21(1):70-3. PubMed ID: 10029818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-HI can cause a severe delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease patients.
    Ibanez C; Habibi A; Mekontso-Dessap A; Chadebech P; Chami B; Bierling P; Galactéros F; Rieux C; Nataf J; Bartolucci P; Peyrard T; Pirenne F
    Transfusion; 2016 Jul; 56(7):1828-33. PubMed ID: 27145018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease.
    Noizat-Pirenne F; Habibi A; Mekontso-Dessap A; Razazi K; Chadebech P; Mahevas M; Vingert B; Bierling P; Galactéros F; Bartolucci P; Michel M
    Vox Sang; 2015 Apr; 108(3):262-7. PubMed ID: 25523469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of delayed hemolytic transfusion reaction in sickle cell disease: Prevention, diagnosis, treatment.
    Pirenne F; Bartolucci P; Habibi A
    Transfus Clin Biol; 2017 Sep; 24(3):227-231. PubMed ID: 28669521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease.
    Balbuena-Merle R; Hendrickson JE
    Transfus Clin Biol; 2019 May; 26(2):112-115. PubMed ID: 30857806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Two serial events of delayed hemolytic transfusion reactions due to different primary immune response-induced irregular antibodies].
    Mizuno K; Yamazaki R; Uemura T; Koda Y; Kikuchi T; Mori T
    Rinsho Ketsueki; 2020; 61(10):1482-1486. PubMed ID: 33162444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The differentiation of delayed hemolytic and delayed serologic transfusion reactions: incidence and predictors of hemolysis.
    Vamvakas EC; Pineda AA; Reisner R; Santrach PJ; Moore SB
    Transfusion; 1995 Jan; 35(1):26-32. PubMed ID: 7998064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab.
    Gupta S; Fenves A; Nance ST; Sykes DB; Dzik WS
    Transfusion; 2015 Mar; 55(3):623-8. PubMed ID: 25257194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab.
    Boonyasampant M; Weitz IC; Kay B; Boonchalermvichian C; Liebman HA; Shulman IA
    Transfusion; 2015 Oct; 55(10):2398-403. PubMed ID: 25989361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delayed hemolytic transfusion reaction in the French hemovigilance system.
    Rieux C; Brittenham G; Bachir D; De Meyer E; Boudjedir K;
    Transfus Clin Biol; 2019 May; 26(2):109-111. PubMed ID: 30910456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peripartum hyperhemolysis prophylaxis and management in sickle cell disease: A case report and narrative review.
    Vasanthamohan L; Choo S; Marshall T; Symons YT; Matsui D; Eastabrook G; Solh Z
    Transfusion; 2020 Oct; 60(10):2448-2455. PubMed ID: 32851670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delayed Hemolytic Transfusion Reaction With Hyperhemolysis Syndrome Due to Anti-M Alloantibody in Myelofibrosis: A Case Report.
    Alsoreeky MS; Lutfi LK; Altamimi AA; Haddad TH; Khalayleh MS; Alkader MS
    Cureus; 2023 Dec; 15(12):e50717. PubMed ID: 38234941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.